Results 251 to 260 of about 419,158 (294)
Some of the next articles are maybe not open access.
Mergent's Dividend Achievers, 2007
AbstractPharmaceuticals (MIC: 9.1 SIC: 2834 NAIC: 325412)Pfizer is engaged in discovering, developing, manufacturing and marketing prescription medicines for humans and animals. Co. operates in two business segments: Pharmaceutical and Animal Health. Co.'s Pharmaceutical segment develops and manufactures products that treat cardiovascular and metabolic
openaire +2 more sources
AbstractPharmaceuticals (MIC: 9.1 SIC: 2834 NAIC: 325412)Pfizer is engaged in discovering, developing, manufacturing and marketing prescription medicines for humans and animals. Co. operates in two business segments: Pharmaceutical and Animal Health. Co.'s Pharmaceutical segment develops and manufactures products that treat cardiovascular and metabolic
openaire +2 more sources
Mergent's Dividend Achievers, 2008
AbstractPharmaceuticals (MIC: 9.1 SIC: 2834 NAIC: 325412)Pfizer discovers, develops, produces and markets prescription medicines for humans and animals. Co. has two key segments: Pharmaceutical, which develops and produces products that treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and ...
openaire +2 more sources
AbstractPharmaceuticals (MIC: 9.1 SIC: 2834 NAIC: 325412)Pfizer discovers, develops, produces and markets prescription medicines for humans and animals. Co. has two key segments: Pharmaceutical, which develops and produces products that treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and ...
openaire +2 more sources
IDrugs : the investigational drugs journal, 1999
Voriconazole is undergoing phase III trials by Pfizer as a potential treatment for resistant systemic aspergillosis, candidosis and other emerging fungal infections seen in immunocompromised patients [201603,320737]. The compound demonstrated efficacy in patients in whom amphotericin had failed to control infection [167646].
Verweij, P.E. +2 more
openaire +2 more sources
Voriconazole is undergoing phase III trials by Pfizer as a potential treatment for resistant systemic aspergillosis, candidosis and other emerging fungal infections seen in immunocompromised patients [201603,320737]. The compound demonstrated efficacy in patients in whom amphotericin had failed to control infection [167646].
Verweij, P.E. +2 more
openaire +2 more sources
Current opinion in investigational drugs (London, England : 2000), 2003
Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory lipid-regulating agent under development by Pfizer (formerly Parke-Davis) for the potential treatment of hyperlipidemia and atherosclerosis. The compound is currently undergoing phase III clinical trials [371470].
John R, Burnett, Murray W, Huff
openaire +1 more source
Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory lipid-regulating agent under development by Pfizer (formerly Parke-Davis) for the potential treatment of hyperlipidemia and atherosclerosis. The compound is currently undergoing phase III clinical trials [371470].
John R, Burnett, Murray W, Huff
openaire +1 more source
Mergent's Dividend Achievers, 2004
AbstractPharmaceuticals (MIC: 9.1 SIC: 2834 NAIC:325412)Pfizer is a research‐based, global pharmaceutical company that discovers, develops, manufactures and markets medicines for humans and animals as well as consumer healthcare products. The products include Norvasc, for the treatment of hypertension and angina, Zyrtec, an anti‐allergy medicine ...
openaire +1 more source
AbstractPharmaceuticals (MIC: 9.1 SIC: 2834 NAIC:325412)Pfizer is a research‐based, global pharmaceutical company that discovers, develops, manufactures and markets medicines for humans and animals as well as consumer healthcare products. The products include Norvasc, for the treatment of hypertension and angina, Zyrtec, an anti‐allergy medicine ...
openaire +1 more source
IDrugs : the investigational drugs journal, 2004
Canertinib, a water-soluble, orally available analog of PD-169414 (Pfizer Inc), is an EGFR tyrosine kinase inhibitor under development by Pfizer Inc as a potential treatment for cancer.
openaire +1 more source
Canertinib, a water-soluble, orally available analog of PD-169414 (Pfizer Inc), is an EGFR tyrosine kinase inhibitor under development by Pfizer Inc as a potential treatment for cancer.
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2003
Pfizer has developed and launched eletriptan, a 5-HT1B/1D agonist, for the potential treatment of migraine with and without aura. Eletriptan has 6-fold greater affinity for the 5-HT1D receptor than sumatriptan, and a 3-fold greater affinity for the 5-HT1B receptor [249570].
Paul J L M, Strijbos +2 more
openaire +1 more source
Pfizer has developed and launched eletriptan, a 5-HT1B/1D agonist, for the potential treatment of migraine with and without aura. Eletriptan has 6-fold greater affinity for the 5-HT1D receptor than sumatriptan, and a 3-fold greater affinity for the 5-HT1B receptor [249570].
Paul J L M, Strijbos +2 more
openaire +1 more source